GlassScriptPhysician profile
Daniel R Kelleher
NPI 1740278589
$10,406.38
in general payments reported to CMS, 2019-2025
29 companies · $1,556 in 2025
The $1,556 reported for 2025 was more than what 91% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,310 · 2020: $1,313 · 2021: $1,914 · 2022: $1,406 · 2023: $1,602 · 2024: $1,305 · 2025: $1,556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,463.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,230.29 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,120.75 | 2019-2025 | Austedo, Austedo Xr, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $822.80 | 2021-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $814.95 | 2020-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $747.86 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $691.53 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $689.37 | 2019-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $590.04 | 2019-2022 | |
| Lundbeck LLC | $501.97 | 2019-2025 | Rexulti |
| Allergan, INC. | $460.83 | 2019-2020 | |
| Tris Pharma INC | $404.37 | 2019-2025 | Dyanavel Xr |
| Corium, LLC | $394.16 | 2022-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $313.51 | 2025 | Fanapt |
| Jazz Pharmaceuticals INC. | $287.18 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $265.61 | 2019-2024 | Spravato |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $206.58 | 2019-2025 | Relexxii, Methylphenidate Hydrochloride |
| Ironshore Pharmaceuticals INC. | $170.82 | 2021-2023 | Jornay Pm |
| Axsome Therapeutics, INC. | $140.94 | 2022-2023 | Auvelity |
| Adlon Therapeutics L.P. | $138.39 | 2020-2021 | |
| Rhodes Pharmaceuticals L.P. | $107.86 | 2019 | |
| Avanir Pharmaceuticals, INC. | $89.99 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $55.31 | 2025 | Cobenfy |
| Arbor Pharmaceuticals, INC. | $54.30 | 2021 | |
| Avion Pharmaceuticals | $24.16 | 2023 | Methylphenidate Hydrochloride |
| Neos Therapeutics, LP | $21.11 | 2023 | Adzenys Xr-Odt |
| Shire North American Group INC | $17.48 | 2019 | |
| Almatica Pharma LLC | $16.10 | 2025 | Loreev Xr |
| Collegium Pharmaceutical, INC. | $15.75 | 2025 | Jornay Pm |
| Harmony Biosciences LLC | $12.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kelleher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.